EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Disease‐free survival as a surrogate outcome for localized kidney cancer—A systematic review and meta‐analysis

Constanza Martinez, David Chen, Russell Leong iD, Nicholas Lum, Karren Xiao, Laith Almasri, Christian K Kollmannsberger, Srinivas Raman

Cancer · 15.08.2026 · 132 (16)

DOI: 10.1002/cncr.70567 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer, online erschienen am 12.08.2026. Verfasst von Constanza Martinez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, McGill University Health Center, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Disease‐free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma ( R CC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting.

Methods

The authors conducted a systematic review and trial‐level meta‐analysis of randomized controlled trials assessing systemic or perioperative therapies in patients with localized RCC. Databases were searched from inception to June 10, 2025. Trial‐level surrogacy between DFS and OS was assessed using weighted least‐squares meta‐regression of log‐transformed hazard ratios (HRs), and the surrogate threshold effect was estimated.

Results

In total, 25 randomized controlled trials were analyzed; 13 trials, analyzed as 15 study‐level units comprising 9594 patients, reported HRs for both OS and DFS. DFS demonstrated a strong correlation with OS (weighted Pearson correlation coefficient, 0.75; 95% confidence level, 0.55–0.91; corresponding coefficient of determination, 0.57). The surrogate threshold effect analysis identified a DFS HR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsCarcinoma, Renal CellHumansDisease-Free SurvivalRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

disease‐free survivaloverall survivalrandomized controlled trialsrenal cell carcinomasurrogate end points

Autor:innen und Institutionen

  • Department of Radiation Oncology, McGill University Health Center, Montreal, Quebec, Canada.
  • Radiation Medicine Program, Princess Margaret Hospital Cancer Center, Toronto, Ontario, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Department of Medical Oncology, British Columbia Cancer Vancouver, Vancouver, British Columbia, Canada.
  • Department of Radiation Oncology, British Columbia Cancer Vancouver, Vancouver, British Columbia, Canada.

ORCID-Profile: Russell Leong

Zitieren

APA

Martinez, C., Chen, D., Leong, R., Lum, N., Xiao, K., Almasri, L., Kollmannsberger, C. K., & Raman, S. (2026). Disease‐free survival as a surrogate outcome for localized kidney cancer—A systematic review and meta‐analysis. Cancer, 132(16). https://doi.org/10.1002/cncr.70567

Vancouver

Martinez C, Chen D, Leong R, Lum N, Xiao K, Almasri L, et al. Disease‐free survival as a surrogate outcome for localized kidney cancer—A systematic review and meta‐analysis. Cancer. 2026;132(16). doi:10.1002/cncr.70567

BibTeX
@article{Martinez2026,
  author = {Martinez, Constanza and Chen, David and Leong, Russell and Lum, Nicholas and Xiao, Karren and Almasri, Laith and Kollmannsberger, Christian K and Raman, Srinivas},
  title = {Disease‐free survival as a surrogate outcome for localized kidney cancer—A systematic review and meta‐analysis},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {16},
  doi = {10.1002/cncr.70567}
}
Kostenlos starten →